drugset / Trial / NCT07027527
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).
Timeline
- Start
- 2025-06-04
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG777 | Monoclonal antibody | — | Subcutaneous |
| Subject | APG990 | Unknown | — | Subcutaneous |
| Comparator | Dupilumab | Monoclonal antibody | — | Subcutaneous |